Awaiting development: Guidance and quality standards

Showing 231 to 240 of 362

Guidance and quality standards awaiting development
Title	Type
Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]	Technology appraisal guidance
Povorcitinib for treating non-segmental vitiligo [GID-TA12019]	Technology appraisal guidance
Povorcitinib for treating prurigo nodularis [GID-TA12018]	Technology appraisal guidance
Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]	Technology appraisal guidance
Pridopidine for treating Huntington's disease [ID6525]	Technology appraisal guidance
Procalcitonin to guide decisions on stopping antibiotics in people with confirmed or highly suspected sepsis	HealthTech guidance
ProKnow cloud-based system for radiotherapy data storage, communication and management	HealthTech guidance
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]	Technology appraisal guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]	Technology appraisal guidance
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]	Technology appraisal guidance